Doz

COVID-19 vaccine (mRNA)

واکسن کووید-۱۹ (mRNA)

⚠ Unverified

🦠 Antiinfectives For Systemic UsemRNA vaccine

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA125742ATC J07BN01

Market / country: 🇺🇸 USA

Comirnaty (US)

🧮 Dose calculator

COVID-19 · Regimen source: FDA Comirnaty · 2.3FDA Comirnaty · 2.2

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ Severe allergic reaction (anaphylaxis) to a vaccine component or a previous dose of a Pfizer-BioNTech COVID-19 vaccine. FDA Comirnaty · 4

Warnings

  • • Myocarditis and pericarditis (mainly young males, within days of vaccination); syncope. FDA Comirnaty · 5

Formulations

  • 0.3 mL single dose (5–11 y vial; ≥12 y prefilled syringe) — injection 🇺🇸 USA FDA Comirnaty · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Comirnaty · 8.1

    “Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Comirnaty · 8.2

    “Data are not available to assess the effects of COMIRNATY on the breastfed infant or on milk production/excretion.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Comirnaty · 8.4

    “Safety and effectiveness of COMIRNATY in individuals 5 years through 17 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 is based on safety and effectiveness data in this age group and in adults [see Adverse Reactions (6) and Clinical Studies (14) ] .”
  • 👴 Older adultsNo specific problem stated

    Label: no specific difference or dose adjustment stated for older adults. FDA Comirnaty · 8.5

    “No overall differences in safety or effectiveness were observed between these recipients and younger recipients.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav